Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 1997

View Archived Issues

Chiron: Q3 1997 highlights

Sequus: Q3 1997 highlights

SangStat Medical: Q3 1997 highlights

Celgene: Q3 1997 highlights

Bausch & Lomb to acquire Chiron Vision

Promising phase III results reported for KeraVision ring

Factor Xa inhibitors prepared at DuPont Merck

NeuroSearch describes tropane derivatives that inhibit neurotransmitter reuptake

Novel class of compound enhances IFN-gamma and NT-3 activity

HMR claims dual H1/NK1 antagonists for allergic/inflammatory disorders

Bristol-Myers Squibb prepares protein farnesyltransferase inhibitors

New alpha-1-antitrypsin test launched in U.S.

Chiroscience develops new TNF/PDE IV inhibitors

Clinical trials planned for CEP-1347/KT-7515 in AD

Sequana and Glaxo Wellcome revise diabetes/obesity alliance

Oral prodrugs of novel carbapenems prepared at Wyeth-Ayerst

Preclinical results with Ergo Science's neuroendocrine resetting therapy

Phase III safety and efficacy data reported for one-alpha D2

GelTex submits NDA for RenaGel

Arris and Sequana to merge

New human rabies vaccine cleared in U.S.

Novel antihypertensive agent developed in Taiwan

Effects of riluzole on ischemia-induced glutamate accumulation in rabbits

U.S. patent issued for ABS 200 series

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 22, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.